| scholarly article | Q13442814 |
| P2093 | author name string | James F Fries | |
| Michael M Ward | |||
| Mary Chester M Wasko | |||
| Jennifer R Elliott | |||
| Helen B Hubert | |||
| Michael E Luggen | |||
| Vijaya Bharathi Lingala | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| hydroxychloroquine | Q421094 | ||
| P304 | page(s) | 187-193 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | |
| P478 | volume | 298 |
| Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
| Q35102474 | Advances in the medical treatment of rheumatoid arthritis |
| Q92037151 | American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in |
| Q64882267 | Anti-inflammatory therapy for cardiovascular disease. |
| Q36073241 | Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial |
| Q41939554 | Antimalarials. A treatment option for every lupus patient!? |
| Q33650548 | Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients |
| Q42103591 | Association of MMP-8 with obesity, smoking and insulin resistance |
| Q84430476 | Atherosclerosis risk factors in systemic lupus erythematosus |
| Q36421188 | Autoimmune thyroid disease in rheumatoid arthritis: a global perspective |
| Q37815217 | Autophagic degradation of mitochondria in white adipose tissue differentiation |
| Q38209287 | Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes |
| Q102059170 | COVID-19 and diabetes mellitus: from pathophysiology to clinical management |
| Q91776881 | Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
| Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
| Q47940789 | Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China |
| Q92118967 | Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? |
| Q34354276 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q36754793 | Chloroquine increases phosphorylation of AMPK and Akt in myotubes. |
| Q31077662 | Comparative effectiveness research with administrative health data in rheumatoid arthritis |
| Q38845570 | Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? |
| Q35057273 | DMPPQA, a novel angiogenesis inhibitor, induces apoptosis in human colon cancer HCT-116 cells and HUVECs |
| Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
| Q37859679 | Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease |
| Q37799813 | Drug-induced hypoglycaemia: an update |
| Q33819280 | Effect of atorvastatin and hydroxychloroquine combination on blood glucose in alloxan-induced diabetic rats |
| Q35742831 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial |
| Q87586879 | Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis |
| Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
| Q22676705 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) |
| Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q36877859 | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients |
| Q88376197 | Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis |
| Q36277899 | Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus |
| Q35519392 | Hydroxychloroquine as a glucose lowering drug |
| Q36906782 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. |
| Q41915768 | Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. |
| Q36246086 | Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals |
| Q93740054 | Hydroxychloroquine may help prevent diabetes |
| Q41918910 | Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study |
| Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
| Q34162739 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus |
| Q39144641 | Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study |
| Q88400696 | Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis |
| Q41953362 | Hydroxychloroquine: a diabetic drug in disguise? |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
| Q38927961 | Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes |
| Q61811391 | Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis |
| Q64889511 | Impact of Cumulative Corticosteroid Dosage on Preventable Hospitalization among Taiwanese Patients with Ankylosing Spondylitis and Inflammatory Bowel Disease. |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q34459100 | Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease |
| Q51152425 | Inflammation-related cardiovascular morbidity : Pathophysiology and therapy |
| Q91598766 | Insights and Implications of the VA Rheumatoid Arthritis Registry |
| Q36675381 | Integration of cellular bioenergetics with mitochondrial quality control and autophagy |
| Q92434438 | Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q37058791 | Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion |
| Q33602858 | Metabolic abnormalities and cardiovascular risk factors in children with myositis |
| Q89285609 | Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article |
| Q90397948 | Patients with Axial Spondyloarthritis Are at Risk of Developing Adhesive Capsulitis: Real-World Evidence Database Study in Taiwan |
| Q46089585 | Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis |
| Q37549027 | Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair? |
| Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
| Q38149252 | Rheumatoid arthritis and cardiovascular disease |
| Q82076745 | Rheumatoid arthritis and cardiovascular disease |
| Q37691220 | Rheumatoid arthritis is associated with reduced adiposity but not with unfavorable major cardiovascular risk factor profiles and enhanced carotid atherosclerosis in black Africans from a developing population: a cross-sectional study |
| Q37169479 | Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis |
| Q34348857 | Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis |
| Q99631317 | Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study |
| Q33838440 | Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study |
| Q41929021 | Safety of immunosuppressants |
| Q41919952 | Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort |
| Q26852726 | Targeting inflammation in diabetes: Newer therapeutic options |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q37261219 | The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition |
| Q39882878 | The lysosome among targets of metformin: new anti-inflammatory uses for an old drug? |
| Q35581498 | Therapeutic approaches to target inflammation in type 2 diabetes |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q82101554 | [Diabetes and rheumatism: is diabetes mellitus also an inflammatory disease?] |
| Q81732655 | [What's new in medicine in 2007?] |
Search more.